7-methoxybenzoxazole | 175211-12-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 7-methoxybenzoxazole
• 英文别名: 7-methoxybenzo[d]oxazole；7-methoxy-1,3-benzoxazole
• CAS: 175211-12-8
• 化学式: C₈H₇NO₂
• 分子量: 149.149
• InChiKey: QNCZYKAFILNYTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-methoxybenzoxazole 在 aluminum (III) chloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 N-溴代丁二酰亚胺(NBS) 、 potassium carbonate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 28.0h， 生成 tert-butyl (7-((4,4-difluorocyclohexyl)methoxy)benzo[d]oxazol-4-yl)carbamate
  参考文献：
  名称：

  [EN] TEAD INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE TEAD ET LEURS UTILISATIONS

  摘要：

  本公开提供化合物及其药学上可接受的组合物，以及使用它们的方法。

  公开号：

  WO2023009785A1
• 作为产物：
  描述：

  6-甲氧基-2-硝基苯酚 在 palladium 10% on activated carbon 、 氢气 、 对甲苯磺酸 作用下， 以 甲醇 为溶剂， 反应 16.0h， 生成 7-methoxybenzoxazole
  参考文献：
  名称：

  [EN] TEAD INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE TEAD ET LEURS UTILISATIONS

  摘要：

  本公开提供化合物及其药学上可接受的组合物，以及使用它们的方法。

  公开号：

  WO2023009785A1

文献信息

• Inhibitors of interleukin-1.beta. converting enzyme
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US05874424A1

  公开（公告）日：1999-02-23

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against an IL-1 mediated disease, an apoptosis mediated disease, AML, CML, melanoma, myeloma, Kaposi's sarcoma, graft vs host disease, rheumatoid arthritis, inflammatory bowel disorder, psoriasis, osteoarthritis, myeloma, apoptosis, sepsis, rheumatoid arthritis, asthma, Alzheimer's disease, Parkinson's disease, and ischemic heart disease diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一类新型化合物，这些化合物是白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可以有利地用作对抗IL-1介导疾病、凋亡介导疾病、AML、CML、黑色素瘤、骨髓瘤、卡波西肉瘤、移植物抗宿主病、类风湿性关节炎、炎症性肠病、牛皮癣、骨关节炎、骨髓瘤、凋亡、败血症、类风湿性关节炎、哮喘、阿尔茨海默病、帕金森病和缺血性心脏病等疾病的药剂。本发明还涉及抑制ICE活性的方法以及使用本发明的化合物和组合物治疗白细胞介素-1介导疾病的方法。
• Inhibitors of interleukin-1&bgr; Converting enzyme inhibitors
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US06204261B1

  公开（公告）日：2001-03-20

  The present invention relates to pyradazino[1,2-a][1,2]diazepine-1-carboxamide compounds of formula: which compounds are inhibitors of interleukin-1beta converting enzyme.

  这项发明涉及公式如下的吡啶并[1,2-a][1,2]二氮杂环庚烷-1-羧酰胺化合物，这些化合物是白细胞介素-1β转化酶的抑制剂。
• Inhibitors of interleukin-1beta converting enzyme
  申请人：Batchelor James Mark

  公开号：US20050143436A1

  公开（公告）日：2005-06-30

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一类新型化合物，这些化合物是白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可以有利地用作对抗IL-1、凋亡、IGIF和IFN-γ介导的疾病、炎症性疾病、自身免疫疾病、破坏性骨疾病、增生性疾病、传染性疾病、退行性疾病和坏死性疾病的药剂。本发明还涉及抑制ICE活性的方法，用于治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病，以及使用本发明的化合物和组合物减少IGIF和IFN-γ的产生的方法。本发明还涉及制备N-酰氨基化合物的方法。
• [EN] PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PYRAZOLOPYRIMIDINONE ET LEURS UTILISATIONS
  申请人：ADURO BIOTECH INC

  公开号：WO2019055750A1

  公开（公告）日：2019-03-21

  The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

  本发明涉及吡唑吡咪啉酮化合物。本发明还涉及含有这些化合物的药物组合物，以及通过向需要的受试者施用这些化合物和药物组合物来治疗自身免疫、炎症和神经退行性疾病的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。
• Inhibitors of interleukin-1 beta converting enzyme
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20020099042A1

  公开（公告）日：2002-07-25

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以优势地用作对白细胞介素-1介导的疾病，包括炎症性疾病、自身免疫疾病和神经退行性疾病的治疗剂。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法和治疗白细胞介素-1介导疾病的方法。